Petra Langerbeins und Ibrutinib - Info zur Person

(1 - 11 von 11

)

JNCCN CLL - CLL12 Trial: Ibrutinib Improves Outcomes in...

jnccn360.org

... and time to next treatment] in patients with treatment-naive early-stage CLL when compared to placebo,” concluded Petra Langerbeins, MD, ...

Ibrutinib in early and late CLL: news from EHA | Lymphoma Hub

lymphomahub.com

... phase II VISION/ HOVON 141 (HOV141) trial.1 While Petra Langerbeins from the University of Cologne, Köln, DE, on Sunday 16 March 2019, ...

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage ...

ecancer.org

CLL12 will be presented tomorrow in the late breaking session by Dr Petra Langerbeins who has been the lead in this study for several years ...

Petra Langerbeins, Ibrutinib versus placebo in patients with ...

www.iwcll.org

› resources

DCLLSG | CLL12 Studie

www.dcllsg.de

Eine placebo-kontrollierte, doppelblinde, randomisierte, multizentrische dreiarmige Phase III Studie zu Effektivität und Sicherheit von Ibrutinib vs. Placebo...

Klinische Studien - Onkologie Schwabing - …

www.muenchen-klinik.de

LKP: Dr. Petra Langerbeins. CLL13 (GAIA) Erstlinientherapie fitter Patienten ohne Komorbiditäten. Gegen FCR/BR (Stratifizierung nach Alter) als Standardarm werden drei chemotherapiefreie Arme getestet: Venetoclax plus Rituximab, vs. Venetoclax plus Obinutuzumab vs. Venetoclax plus Obinutuzumab plus Ibrutinib. EudraCT-Nr